The business development department undertakes the research and evaluation of potential future collaborations with foreign companies, for products under evaluation or in the process of approval by the American Medicines Agency (FDA) or the European Medicines Agency (EMEA). The purpose of the department is to reach a representation agreement with the MAHs for the market of Greece, Cyprus and beyond.

In addition, the business development department oversees seeking partners to countries outside Greece and Cyprus, in order to be partners for the company’s export activity.